InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.082 0.001 (1.20%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$40 Notice of Extraordinary General Meeting/Proxy Form 27 May 2025 12:47PM $0.017 $0.082 risen by 382.35%
$40 Notification regarding unquoted securities - IMU 23 May 2025 4:11PM $0.017 $0.082 risen by 382.35%
$40 Notification of cessation of securities - IMU 21 May 2025 4:42PM $0.017 $0.082 risen by 382.35%
$40 Proposed Consolidation of Capital 16 May 2025 12:56PM $0.023 $0.082 risen by 256.52%
$40 Letter to Shareholders 1 May 2025 11:59AM $0.024 $0.082 risen by 248.94%
$40 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 8:47AM $0.025 $0.082 risen by 228%
$40 Application for quotation of securities - IMU 14 Apr 2025 4:45PM $0.026 $0.082 risen by 215.38%
$40 Notification of cessation of securities - IMU 11 Apr 2025 4:55PM $0.024 $0.082 risen by 241.67%
$40 Notification regarding unquoted securities - IMU 11 Apr 2025 4:50PM $0.024 $0.082 risen by 241.67%
$40 Investor Update & FAQ Webinar 10 Apr 2025 9:35AM $0.024 $0.082 risen by 241.67%
$40 1st dose level cleared IV combination arm onCARlytics trial 3 Apr 2025 8:51AM $0.030 $0.082 risen by 173.33%
$40 Azer-cel Granted FDA Fast Track Designation in Blood Cancer 19 Mar 2025 9:02AM $0.035 $0.082 risen by 134.29%
$40 Application for quotation of securities - IMU 13 Mar 2025 5:51PM $0.034 $0.082 risen by 141.18%
$40 S&P DJI Announces March 2025 Quarterly Rebalance 7 Mar 2025 5:01PM $0.036 $0.082 risen by 127.78%
$40 Darren Keamy Appointed CFO and Company Secretary 4 Mar 2025 9:01AM $0.036 $0.082 risen by 127.78%
$40 Half Yearly Report and Accounts 28 Feb 2025 10:00AM $0.038 $0.082 risen by 115.79%
$40 Imugene Granted India Patent for Oncolytic Virotherapy CF33 27 Feb 2025 8:59AM $0.036 $0.082 risen by 127.78%
$40 Imugene OnCARlytics Patent Allowance in China 26 Feb 2025 8:58AM $0.036 $0.082 risen by 127.78%
$40 Change of Directors Interest Notice x 5 21 Feb 2025 4:53PM $0.038 $0.082 risen by 115.79%
$40 Notification regarding unquoted securities - IMU 21 Feb 2025 4:46PM $0.038 $0.082 risen by 115.79%
$40 Application for quotation of securities - IMU 21 Feb 2025 4:45PM $0.038 $0.082 risen by 115.79%
$40 Azer-cel demonstrates two additional Complete Responses 14 Feb 2025 8:44AM $0.039 $0.082 risen by 110.26%
$40 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 8:50AM $0.037 $0.082 risen by 121.62%
$40 Notification of cessation of securities - IMU 29 Jan 2025 4:58PM $0.039 $0.082 risen by 110.26%
$40 Application for quotation of securities - IMU 29 Jan 2025 4:56PM $0.039 $0.082 risen by 110.26%

151 - 175 of 1188 results

Page 7 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.